{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:38:40Z","timestamp":1791520720391,"version":"4.3.4"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"Supplement_9","license":[{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The opioid epidemic in the United States, along with a lack of adequate harm reduction services, has contributed to a sharp rise in hepatitis C virus (HCV) infections. Despite considerable evidence of the effectiveness of HCV treatment in people who inject drugs (PWID), and recommendations from clinical guidelines to prioritize treatment in PWID, there are multiple barriers to broad uptake of HCV treatment. These barriers exist at the systems level, as well as at the level of medical providers and patients. Interventions to remove treatment barriers in the United States include harm reduction services, simplifying HCV testing algorithms, improved linkage to HCV care services, and application of new treatment models including colocating services at substance use disorder treatment programs. By following the lead of other countries who have addressed the barriers to HCV treatment, the United States has opportunities to do better in addressing the consequences of the opioid epidemic, including chronic HCV infection.<\/jats:p>","DOI":"10.1093\/infdis\/jiaa574","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T19:13:15Z","timestamp":1599246795000},"page":"S773-S781","source":"Crossref","is-referenced-by-count":36,"title":["We Must Do Better: Addressing HCV Treatment Barriers in Persons Who Inject Drugs in the United States"],"prefix":"10.1093","volume":"222","author":[{"given":"Stacey B","family":"Trooskin","sequence":"first","affiliation":[{"name":"Philadelphia FIGHT Community Health Centers, Philadelphia, Pennsylvania, USA"},{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Dore","sequence":"additional","affiliation":[{"name":"The Kirby Institute, University of New South Wales, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Kostman","sequence":"additional","affiliation":[{"name":"Philadelphia FIGHT Community Health Centers, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,27]]},"reference":[{"key":"2020120621133594300_CIT0001","volume-title":"Key substance use and mental health indicators in the United States: results from the 2016 National Survey on Drug Use and Health. HHS Publication No. SMA 17\u20135044, NSDUH Series H-52","author":"Substance Abuse and Mental Health Services Administration","year":"2017"},{"key":"2020120621133594300_CIT0002","author":"Substance Abuse and Mental Health Services Administration"},{"key":"2020120621133594300_CIT0003","author":"Centers"},{"key":"2020120621133594300_CIT0004","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1086\/588297","article-title":"Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994","volume":"46","author":"Amon","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020120621133594300_CIT0005","author":"American Association for the Study of Liver Diseases\/Infectious Diseases Society of America."},{"key":"2020120621133594300_CIT0006","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0140-6736(18)32277-3","article-title":"Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model","volume":"393","author":"Heffernan","year":"2019","journal-title":"Lancet"},{"key":"2020120621133594300_CIT0007","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/cid\/ciw580","article-title":"Efficacy and safety of ledipasvir\/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: analysis of phase 3 ION trials","volume":"63","author":"Grebely","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020120621133594300_CIT0008","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jhep.2015.03.029","article-title":"Ombitasvir\/paritaprevir\/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine","volume":"63","author":"Lalezari","year":"2015","journal-title":"J Hepatol"},{"key":"2020120621133594300_CIT0009","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/cid\/ciw579","article-title":"Efficacy and safety of sofosbuvir\/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials","volume":"63","author":"Grebely","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020120621133594300_CIT0010","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial","volume":"165","author":"Dore","year":"2016","journal-title":"Ann Int Med"},{"key":"2020120621133594300_CIT0011","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S2468-1253(17)30075-4","article-title":"Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study","volume":"2","author":"Grebely","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2020120621133594300_CIT0012","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S2468-1253(18)30304-2","article-title":"Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis","volume":"3","author":"Hajarizadeh","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2020120621133594300_CIT0013","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1093\/cid\/ciz696","article-title":"Efficacy of direct-acting antivirals for chronic hepatitis C virus infection in people who inject drugs or receive opioid substitution therapy: a systematic review and meta-analysis","volume":"70","author":"Graf","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2020120621133594300_CIT0014","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/jvh.12129","article-title":"Uptake of hepatitis C treatment among people who inject drugs attending needle and syringe programs in Australia, 1999\u20132011","volume":"21","author":"Iversen","year":"2014","journal-title":"J Viral Hep"},{"key":"2020120621133594300_CIT0015","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/add.14393","article-title":"Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs","volume":"114","author":"Grebely","year":"2019","journal-title":"Addiction"},{"key":"2020120621133594300_CIT0016","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.drugalcdep.2018.11.026","article-title":"Hepatitis C continuum of care and utilization of healthcare and harm reduction services among persons who inject drugs in Seattle","volume":"195","author":"Tsui","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"2020120621133594300_CIT0017","doi-asserted-by":"crossref","first-page":"i5199","DOI":"10.1136\/bmj.i5199","article-title":"Breaking down the silo walls","volume":"354","author":"McCartney","year":"2016","journal-title":"BMJ"},{"key":"2020120621133594300_CIT0018","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jvh.13119","article-title":"Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C-SCOPE Study","volume":"26","author":"Litwin","year":"2019","journal-title":"J Viral Hepat"},{"key":"2020120621133594300_CIT0019","author":"Harvard Center for Health Law Policy and Innovation"},{"key":"2020120621133594300_CIT0020","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1086\/381095","article-title":"Syringe distribution to injection drug users for prevention of HIV infection: opinions and practices of health care providers in New York City","volume":"38","author":"Coffin","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020120621133594300_CIT0021","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/jvh.12859","article-title":"Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era","volume":"25","author":"Falade-Nwulia","year":"2018","journal-title":"J Viral Hepat"},{"key":"2020120621133594300_CIT0022","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11904-018-0402-3","article-title":"Implementing treatment of opioid-use disorder in rural settings: a focus on HIV and hepatitis C prevention and treatment","volume":"15","author":"Havens","year":"2018","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2020120621133594300_CIT0023","doi-asserted-by":"crossref","first-page":"107705","DOI":"10.1016\/j.drugalcdep.2019.107705","article-title":"Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists-the practitioner experience","volume":"206","author":"Marshall","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"2020120621133594300_CIT0024","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1093\/infdis\/jis928","article-title":"Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV\/HIV coinfection: action required at the system, provider, and patient levels","volume":"207","author":"Grebely","year":"2013","journal-title":"J Infect Dis"},{"key":"2020120621133594300_CIT0025","doi-asserted-by":"crossref","first-page":"7846","DOI":"10.3748\/wjg.v19.i44.7846","article-title":"Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care","volume":"19","author":"Zeremski","year":"2013","journal-title":"World J Gastroenterol"},{"key":"2020120621133594300_CIT0026","volume-title":"Opportunities to improve opioid use disorder and infectious diseases services: integrating responses to a dual epidemic","author":"National Academies of Sciences, Engineering, and Medicine","year":"2020"},{"key":"2020120621133594300_CIT0027","first-page":"28","volume-title":"Effectiveness of sterile needle and syringe programming in reducing HIV\/AIDS among IDUs","author":"World Health Organization (WHO)","year":"2004"},{"key":"2020120621133594300_CIT0028","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/01.aids.0000192066.86410.8c","article-title":"Reductions in hepatitis C and HIV infections among injecting drug users in New York City, 1990\u20132001","volume":"19","author":"Des Jarlais","year":"2005","journal-title":"AIDS"},{"key":"2020120621133594300_CIT0029","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1001\/jama.2019.10657","article-title":"Opioid injection in rural areas of the United States. A potential obstacle to ending the HIV epidemic","volume":"322","author":"Lerner","year":"2019","journal-title":"JAMA"},{"key":"2020120621133594300_CIT0030","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/journalofethics.2016.18.3.hlaw1-1603","article-title":"Needle exchange programs\u2019 status in US politics","volume":"18","author":"Weinmeyer","year":"2016","journal-title":"AMA J Ethics"},{"key":"2020120621133594300_CIT0031","doi-asserted-by":"crossref","first-page":"e1208","DOI":"10.1016\/S2214-109X(17)30373-X","article-title":"Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review","volume":"5","author":"Larney","year":"2017","journal-title":"Lancet Glob Health"},{"key":"2020120621133594300_CIT0032","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1111\/add.12682","article-title":"The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users","volume":"109","author":"Nolan","year":"2014","journal-title":"Addiction"},{"key":"2020120621133594300_CIT0033","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.15585\/mmwr.mm655051e1","article-title":"Increases in drug and opioid-involved overdose deaths-United States 2010\u20132015","volume":"65","author":"Rudd","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020120621133594300_CIT0034","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s11524-010-9495-8","article-title":"Overdose prevention and naloxone prescription for opioid users in San Francisco","volume":"87","author":"Enteen","year":"2010","journal-title":"J Urban Health"},{"key":"2020120621133594300_CIT0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/ADM.0000000000000374","article-title":"An innovative model for naloxone use within an OTP setting: a prospective cohort study","volume":"12","author":"Katzman","year":"2018","journal-title":"J Addict Med"},{"key":"2020120621133594300_CIT0036","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhep.2019.11.012","article-title":"Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: a meta-analysis","volume":"72","author":"Hajarizadeh","year":"2020","journal-title":"J Hepatol"},{"key":"2020120621133594300_CIT0037","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1473-3099(16)30208-0","article-title":"Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses","volume":"16","author":"Zhou","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2020120621133594300_CIT0038","first-page":"1550","article-title":"Demonstration of homology between IS6110 of Mycobacterium tuberculosis and DNAs of other Mycobacterium spp.?","volume":"55","author":"Kent","year":"2017","journal-title":"J Clin Microbiol"},{"key":"2020120621133594300_CIT0039","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1093\/infdis\/jiy114","article-title":"Evaluation of the Xpert HCV viral load finger-stick point-of-care assay","volume":"217","author":"Lamoury","year":"2018","journal-title":"J Infect Dis"},{"key":"2020120621133594300_CIT0040","first-page":"20191","article-title":"Linkage to care rates among individuals testing positive for chronic hepatitis C infection at substance use treatment centers","volume":"70","author":"Ripkin","year":"2019","journal-title":"Hepatology"},{"key":"2020120621133594300_CIT0041","first-page":"S719","article-title":"Randomized controlled trial of cash incentives or peer mentors to improve HCV linkage and treatment among HIV\/HCV coinfected persons who inject drugs: the CHAMPS Study","volume":"66","author":"Sulkowski","year":"2017","journal-title":"J Hepatol"},{"key":"2020120621133594300_CIT0042","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/M17-0118","article-title":"Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial","volume":"167","author":"Kattakuzhy","year":"2017","journal-title":"Ann Intern Med"},{"key":"2020120621133594300_CIT0043","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1056\/NEJMoa1009370","article-title":"Outcomes of treatment for hepatitis C virus infection by primary care providers","volume":"364","author":"Arora","year":"2011","journal-title":"N Engl J Med"},{"key":"2020120621133594300_CIT0044","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1007\/s10620-013-2810-y","article-title":"Clinical outcomes of hepatitis C treated with pegylated interferon and ribavirin via telemedicine consultation in Northern California","volume":"58","author":"Rossaro","year":"2013","journal-title":"Dig Dis Sci"},{"key":"2020120621133594300_CIT0045","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0027-9684(15)30161-9","article-title":"Improving access to hepatitis C care for urban, underserved patients using a primary care-based hepatitis C clinic","volume":"104","author":"Miller","year":"2012","journal-title":"J Natl Med Assoc"},{"key":"2020120621133594300_CIT0046","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.amjmed.2016.11.019","article-title":"Telemedicine specialty support promotes hepatitis c treatment by primary care providers in the Department of Veterans Affairs","volume":"130","author":"Beste","year":"2017","journal-title":"Am J Med"},{"key":"2020120621133594300_CIT0047","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jsat.2017.01.015","article-title":"Retention in buprenorphine treatment is associated with improved HCV care outcomes","volume":"75","author":"Norton","year":"2017","journal-title":"J Subst Abuse Treat"},{"key":"2020120621133594300_CIT0048","article-title":"High SVR in PWID with HCV despite imperfect medication adherence: data from the ANCHOR study","volume":"68:S1,12A","author":"Kattakuzhy","year":"2018","journal-title":"Hepatology"},{"key":"2020120621133594300_CIT0049","doi-asserted-by":"crossref","first-page":"594","DOI":"10.7326\/M18-1715","article-title":"Intensive models of hepatitis C care for people who inject drugs receiving opioid agonist therapy: a randomized controlled trial","volume":"170","author":"Akiyama","year":"2019","journal-title":"Ann Intern Med"},{"key":"2020120621133594300_CIT0050","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jhep.2017.12.013","article-title":"Modelling the elimination of hepatitis C as a public health threat in Iceland: a goal attainable by 2020","volume":"68","author":"Scott","journal-title":"J Hepatol"},{"key":"2020120621133594300_CIT0051","doi-asserted-by":"crossref","first-page":"e104515","DOI":"10.1371\/journal.pone.0104515","article-title":"Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions","volume":"9","author":"Palmateer","year":"2014","journal-title":"PLoS One"},{"key":"2020120621133594300_CIT0052","author":"World Health Organization"},{"key":"2020120621133594300_CIT0053","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/liv.14324","article-title":"Global timing of hepatitis C virus elimination in high-income countries","volume":"40","author":"Razavi","year":"2020","journal-title":"Liver Int"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/222\/Supplement_9\/S773\/34558968\/jiaa574.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/222\/Supplement_9\/S773\/34558968\/jiaa574.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T04:25:27Z","timestamp":1607315127000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/222\/Supplement_9\/S773\/6007498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,27]]},"references-count":53,"journal-issue":{"issue":"Supplement_9","published-online":{"date-parts":[[2020,11,27]]},"published-print":{"date-parts":[[2020,11,27]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa574","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,15]]},"published":{"date-parts":[[2020,11,27]]}}}